Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung …
PL Su, YL Wu, WY Chang, CL Ho… - Therapeutic …, 2018 - journals.sagepub.com
Introduction: Brain metastases (BM) are common in advanced non-small cell lung cancer
(NSCLC), and the prognosis is poor with few therapeutic options. This study evaluated the …
(NSCLC), and the prognosis is poor with few therapeutic options. This study evaluated the …
Role of epidermal growth factor receptor-tyrosine kinase inhibitors in the management of central nervous system metastases in epidermal growth factor receptor …
U Batra, N Lokeshwar, S Gupta… - Indian Journal of …, 2017 - journals.lww.com
Metastases to central nervous system (CNS) are very common in nonsmall cell lung cancer
(NSCLC) patients with epidermal growth factor receptor (EGFR)-positive mutation. Brain is …
(NSCLC) patients with epidermal growth factor receptor (EGFR)-positive mutation. Brain is …
EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: a pooled analysis of published data
Y Fan, X Xu, C Xie - OncoTargets and therapy, 2014 - Taylor & Francis
Introduction Brain metastases are one of the leading causes of death from non-small-cell
lung cancer (NSCLC). The use of epidermal growth factor receptor (EGFR) tyrosine kinase …
lung cancer (NSCLC). The use of epidermal growth factor receptor (EGFR) tyrosine kinase …
Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy
A Sekine, H Satoh - Medical Oncology, 2017 - Springer
Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)
mutations commonly present brain metastases (BM) at the time of NSCLC diagnosis or …
mutations commonly present brain metastases (BM) at the time of NSCLC diagnosis or …
Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and …
M Hochmair - Targeted Oncology, 2018 - Springer
Brain metastases and/or leptomeningeal disease (LMD) with associated central nervous
system (CNS) metastases are known complications of advanced epidermal growth factor …
system (CNS) metastases are known complications of advanced epidermal growth factor …
Impacts of EGFR mutation and EGFR-TKIs on incidence of brain metastases in advanced non-squamous NSCLC
BX Wang, W Ou, XY Mao, Z Liu, HQ Wu… - Clinical Neurology and …, 2017 - Elsevier
Objective Brain metastases remain lethal in lung cancer patients. The impacts of epidermal
growth factor receptor (EGFR) mutations and EGFR tyrosine kinase inhibitors (TKIs) on the …
growth factor receptor (EGFR) mutations and EGFR tyrosine kinase inhibitors (TKIs) on the …
Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or …
S Heon, BY Yeap, GJ Britt, DB Costa, MS Rabin… - Clinical cancer …, 2010 - AACR
Purpose: Gefitinib and erlotinib can penetrate into the central nervous system (CNS) and
elicit responses in patients with brain metastases (BM) from non–small cell lung cancer …
elicit responses in patients with brain metastases (BM) from non–small cell lung cancer …
EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer
AF Eichler, KT Kahle, DL Wang, VA Joshi… - Neuro …, 2010 - academic.oup.com
A small subset of patients with nonsmall cell lung cancer (NSCLC) harbors mutations in the
epidermal growth factor receptor (EGFR) that predict unique sensitivity to EGFR tyrosine …
epidermal growth factor receptor (EGFR) that predict unique sensitivity to EGFR tyrosine …
The retrospective analysis of the frequency of EGFR mutations and the efficacy of gefitinib in NSCLC patients with brain metastasis.
Z Li, J Lu, Y Zhao, H Guo - Journal of Clinical Oncology, 2011 - ascopubs.org
e18065 Background: Some reports have showed that brain metastasis (BM) in the advanced
NSCLC patients has higher EGFR mutations. Gefitinib (TKI) has shown the effectiveness in …
NSCLC patients has higher EGFR mutations. Gefitinib (TKI) has shown the effectiveness in …
Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy
A Sekine, H Satoh, T Iwasawa, K Tamura… - Medical oncology, 2014 - Springer
The aim of this study was to explore prognostic factors for non-small cell lung cancer
(NSCLC) patients with brain metastases (BM) on the basis of EGFR mutation status. Among …
(NSCLC) patients with brain metastases (BM) on the basis of EGFR mutation status. Among …